Antares Prof High Growth Shares is an Managed Funds investment product that is benchmarked against ASX Index 200 Index and sits inside the Domestic Equity - Long Short Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The Antares Prof High Growth Shares has Assets Under Management of 401.02 M with a management fee of 1.05%, a performance fee of 0.00% and a buy/sell spread fee of 0.3%.
Australian shares disappointed in August with a mild decline given concerns over China’s prospects as well as the Australian consumer. The Utilities and Consumer Staples sectors led the market declines given concerns about the consumer’s ability to absorb higher electricity & gas prices as well as rising mortgage interest rates and rents. Information Technology declined in line with a more cautious view after their recent strong gains. Despite a rebound in the iron ore price to above US$110 per ton, the Resources sector posted a -1.8% negative return with concerns over China’s prospects. There were some positives with surprisingly strong gains for Consumer Discretionary and Real Estate on hopes that the Reserve Bank has ceased raising interest rates.
August is also reporting season for most Australian companies and while results were largely in line with expectations, the prospect of rising costs and a slowing economy saw reasonably soft guidance for the FY24 year which flowed through to earnings downgrades. Sector allocation The Antares High Growth Shares Fund returned -3.0% (net of fees) for the month of August 2023, compared to its benchmark’s -0.7% return.
Detracting value were overweight positions in Iress (IRE), Resmed Inc (RES) and Block Inc (SQ2). IRE’s result was accompanied by its fourth material earnings downgrade in 12 months, citing cost pressures and a weaker revenue outlook.
The company also announced that it would suspend its interim dividend. RES’ 4Q result was below market expectations, driven by lower margins and higher costs. There is also some concern that the increased use of Ozempic for weight loss could reduce the prospect of sleep apnoea and subsequent demand for RES’ machines. Compounding this was the release of clinical trial results by Novo Nordisk, the manufacturer of Ozempic that indicated another of its weight loss products, Wegovy, could reduce the risk of serious heart problems and heart-related death by 20%. Having risen by more than 21% in July, SQ2 shares were sold down in August after reporting its 2Q23 results. This was despite the company exceeding expectations and upgrading full year EBITDA guidance. The decline appears to be driven by the outlook provided by management whereby 3Q23 gross margins were decelerating, as well as overall macroeconomic concerns. A material portion of SQ2’s earnings are exposed to transaction volumes Top 10 share holdings (alphabetical order) in small and medium sized businesses, which are adversely impacted by a slowdown in US consumer spending.
Product Snapshot
Performance Review
Product Overview
Peer Comparison
Product Details